【摘要】 目的探讨恩替卡韦联合霉酚酸酯治疗乙型肝炎病毒相关性肾炎的临床疗效和安全性。方法将63例乙型肝炎病毒相关性肾炎患者分为治疗组30例和对照组33例,治疗组采用恩替卡伟联合霉酚酸酯治疗,对照组采用恩替卡韦治疗,观察治疗前后24 h尿蛋白定量、血清清蛋白(Alb)水平、肝肾功能及不良反应。结果治疗组总有效率为76.7%,高于对照组(48.5%),差异有统计学意义(P<0.05);治疗组Alb水平显著高于对照组(P<0.05),胆固醇(CHOL)、三酰甘油(TG)水平显著低于对照组(P<0.05);两组未见明显不良反应。结论恩替卡伟联合霉酚酸酯是治疗乙型肝炎病毒相关性肾炎的有效方法之一。更多还原

【Abstract】 Objective To investigate the clinical effect and safety of entecavir combined with mycophenolate in the treatment of HBV-related glomerulonephritis(HBV-GN).Methods 63 patients with HBV-GN were divided into the treatment group(n=30) and the control group(n=33).The treatment group was treated by entecavir combined with mycophenolate and the control group was treated with entecavir.The levels of 24 h urinary protein,serum albumin(Alb),liver and kidney function and adverse reactions were observed before and after treatment.Results The total effective rate was 76.7% in the treatment group,which was higher than 48.5% in the control group,difference showing statistical significance(P<0.05).The level of ALB in the treatment group was significantly higher than that in the control group(P<0.05),while the levels of cholesterol(CHOL) and triglyceride(TG) were significantly lower than those in the control group(P<0.05).There was no obvious adverse reaction in the two groups.Conclusion Entecavir.combined with mycophenolate is one of effective methods to treat HBV-GN.更多还原